MedPath
HSA Approval

ISOPRINOSINE SYRUP 250 mg/5 ml

SIN01361P

ISOPRINOSINE SYRUP 250 mg/5 ml

ISOPRINOSINE SYRUP 250 mg/5 ml

May 18, 1988

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantUNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED
Licence HolderUNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

J05AX05

inosine pranobex

Manufacturer Information

UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

SWISS PHARMA RESEARCH LABORATORIES INC

Active Ingredients

METHISOPRINOL

250 mg/5 ml

Inosine Pranobex

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ISOPRINOSINE SYRUP 250 mg/5 ml - HSA Approval | MedPath